Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
A closer look at Akorn, Inc. (NASDAQ:AKRX)'s generics business led Piper Jaffray to turn bullish on the drug manufacturer's stock.
The Analyst
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
Analyst David Amsellem upgraded Akorn from Neutral to Overweight and raised the price target from $5 to $9.
The Thesis
Akorn's EBITDA has declined abruptly since 2015, from more than $450 million to roughly $110 million, Amsellem said in the upgrade note. (See his track record here.)
The drop was largely driven by limited-competition products and brand-like margins, despite the company’s primary focus on ophthalmics and injectables that have positioned it in other areas of the space, the analyst said.
Akorn's operating margins in 2017 were 24 percent before declining to 12 percent in the first half of 2018, Amsellem said.
FREE REPORT: How To Learn Options Trading Fast
In this special report, you will learn the four best strategies for trading options, how to stay safe as a complete beginner, a 411% trade case study, PLUS how to access two new potential winning options trades starting today.Claim Your Free Report Here.
“Larger U.S. generics companies such as Endo International PLC (NASDAQ:ENDP) and Amneal Pharmaceuticals Inc (NYSE:AMRX), both of which certainly have exposure to commodity products, are running at 2018 operating margins of closer to 29 percent (excluding Vasostrict and key brand products) and 25 percent, respectively.”
The other factors behind Piper Jaffray's bullish stance on Akorn are as follows, the analyst said:
- An improved cost structure following the termination of the Fresenius transaction.
- Increased signs of stabilization.
- An improved product concentration, notably with the company’s Accutane generic.
- The potential from complex ophthalmic products that have yet to be announced.
Price Action
Akorn shares were trading up nearly 3 percent to $6.91 off the open Wednesday.
Related Links
The Daily Biotech Pulse: Eiger's Lymphoedema Drug Study Fails, Roche's Sales Rise
Why Raymond James Is Bullish On Deciphera, Dova Pharmaceuticals
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.